carbon monoxide has been researched along with Arthritis, Rheumatoid in 18 studies
Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed)
carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.
Arthritis, Rheumatoid: A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carbon monoxide (CO) is a gas endogenously produced in humans, reported to exhibit anti-inflammatory and cytoprotective effects at low concentration." | 5.51 | Synthesis and Evaluation of Carbonic Anhydrase Inhibitors with Carbon Monoxide Releasing Properties for the Management of Rheumatoid Arthritis. ( Angeli, A; Bartolucci, G; Berrino, E; Bozdag, M; Carta, F; di Cesare Mannelli, L; Ghelardini, C; Menicatti, M; Micheli, L; Milazzo, L; Nocentini, A; Supuran, CT; Vullo, D, 2019) |
| "Vital capacity (VC) and single-breath diffusing capacity for carbon monoxide of the lungs (Dco) were measured and chest X-ray evaluated in 129 patients with rheumatoid arthritis (RA)." | 3.65 | Pulmonary involvement in patients with rheumatoid arthritis. ( Aalto, P; Laitinen, O; Nissilä, M; Salorinne, Y, 1975) |
| "Of the entire cohort (n = 243), systemic sclerosis (SSc)-associated ILD (n = 88, 36%), interstitial pneumonia with autoimmune features (IPAF, n = 56, 23%), rheumatoid arthritis (RA)-associated ILD (n = 42, 17%), and idiopathic inflammatory myopathy (IIM)-associated ILD (n = 26, 11%) were the most common phenotypes." | 1.51 | Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience. ( Chartrand, S; Fischer, A; Lee, JS; Stanchev, L; Swigris, JJ, 2019) |
| "Carbon monoxide (CO) is a gas endogenously produced in humans, reported to exhibit anti-inflammatory and cytoprotective effects at low concentration." | 1.51 | Synthesis and Evaluation of Carbonic Anhydrase Inhibitors with Carbon Monoxide Releasing Properties for the Management of Rheumatoid Arthritis. ( Angeli, A; Bartolucci, G; Berrino, E; Bozdag, M; Carta, F; di Cesare Mannelli, L; Ghelardini, C; Menicatti, M; Micheli, L; Milazzo, L; Nocentini, A; Supuran, CT; Vullo, D, 2019) |
| "Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is associated with significant morbidity and mortality." | 1.46 | The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease. ( Cerri, S; Collard, HR; Elicker, BM; Gross, AJ; Hu, X; Jones, KD; Kim, DS; King, TE; Lee, BY; Lee, JS; Ley, B; Manfredi, A; Morisset, J; Ryu, JH; Sebastiani, M; Tonelli, R; Vittinghoff, E; Wolters, PJ, 2017) |
| "Diffuse bronchiectasis was the main finding." | 1.43 | Preclinical lung disease in early rheumatoid arthritis. ( Dorca, J; Luburich, P; Molina-Molina, M; Narvaez-Garcia, J; Nolla, JM; Robles-Perez, A; Rodriguez-Sanchon, B, 2016) |
| "Among the most common are interstitial lung disease (ILD) and bronchiectasis." | 1.35 | Clinical and high resolution computed tomography characteristics of patients with rheumatoid arthritis lung disease. ( Abdul Manap, R; Azhar Shah, S; Mohd Noor, N; Mohd Shahrir, MS; Shahid, MS; Shahizon Azura, AM, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (27.78) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Chartrand, S | 1 |
| Lee, JS | 3 |
| Swigris, JJ | 2 |
| Stanchev, L | 1 |
| Fischer, A | 2 |
| Tao, S | 1 |
| Cheng, J | 1 |
| Su, G | 1 |
| Li, D | 1 |
| Shen, Z | 1 |
| Tao, F | 1 |
| You, T | 1 |
| Hu, J | 1 |
| Natalini, JG | 1 |
| Morisset, J | 2 |
| Elicker, BM | 2 |
| Jones, KD | 2 |
| Collard, HR | 2 |
| Vittinghoff, E | 1 |
| Lee, BY | 1 |
| Tonelli, R | 1 |
| Hu, X | 1 |
| Ryu, JH | 1 |
| Cerri, S | 1 |
| Manfredi, A | 1 |
| Sebastiani, M | 1 |
| Gross, AJ | 1 |
| Ley, B | 1 |
| Wolters, PJ | 1 |
| King, TE | 1 |
| Kim, DS | 1 |
| Jung, CR | 1 |
| Hsieh, HY | 1 |
| Hwang, BF | 1 |
| Shin, J | 1 |
| Lee, J | 2 |
| Ha, EH | 1 |
| Berrino, E | 1 |
| Milazzo, L | 1 |
| Micheli, L | 1 |
| Vullo, D | 1 |
| Angeli, A | 1 |
| Bozdag, M | 1 |
| Nocentini, A | 1 |
| Menicatti, M | 1 |
| Bartolucci, G | 1 |
| di Cesare Mannelli, L | 1 |
| Ghelardini, C | 1 |
| Supuran, CT | 1 |
| Carta, F | 1 |
| Chi, PL | 1 |
| Chuang, YC | 1 |
| Chen, YW | 1 |
| Lin, CC | 1 |
| Hsiao, LD | 1 |
| Yang, CM | 1 |
| Robles-Perez, A | 1 |
| Luburich, P | 1 |
| Rodriguez-Sanchon, B | 1 |
| Dorca, J | 1 |
| Nolla, JM | 1 |
| Molina-Molina, M | 1 |
| Narvaez-Garcia, J | 1 |
| Franzen, D | 1 |
| Ciurea, A | 1 |
| Bratton, DJ | 1 |
| Clarenbach, CF | 1 |
| Latshang, TD | 1 |
| Russi, EW | 1 |
| Kyburz, D | 1 |
| Kohler, M | 1 |
| Mohd Noor, N | 1 |
| Mohd Shahrir, MS | 1 |
| Shahid, MS | 1 |
| Abdul Manap, R | 1 |
| Shahizon Azura, AM | 1 |
| Azhar Shah, S | 1 |
| POLLERI, A | 1 |
| CANEPA, F | 1 |
| DEGAETANI, G | 1 |
| Mitlyng, BL | 1 |
| Singh, JA | 1 |
| Furne, JK | 1 |
| Ruddy, J | 1 |
| Levitt, MD | 1 |
| Alcaraz, MJ | 1 |
| Guillen, MI | 1 |
| Ferrandiz, ML | 1 |
| Megías, J | 1 |
| Motterlini, R | 1 |
| O'Brodovich, HM | 1 |
| Way, RC | 1 |
| Andrew, M | 1 |
| Dent, PB | 1 |
| Salorinne, Y | 2 |
| Laitinen, O | 1 |
| Nissilä, M | 1 |
| Aalto, P | 1 |
| Renzetti, AD | 1 |
| Kobayashi, T | 1 |
| Bigler, A | 1 |
| Mitchell, MN | 1 |
1 trial available for carbon monoxide and Arthritis, Rheumatoid
| Article | Year |
|---|---|
Use of breath carbon monoxide measurements to assess erythrocyte survival in subjects with chronic diseases.
Topics: Aged; Aged, 80 and over; Anemia; Arthritis, Rheumatoid; Bone Marrow; Breath Tests; Carbon Monoxide; | 2006 |
17 other studies available for carbon monoxide and Arthritis, Rheumatoid
| Article | Year |
|---|---|
Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience.
Topics: Adult; Age Distribution; Age Factors; Aged; Arthritis, Rheumatoid; Autoimmune Diseases; Carbon Monox | 2019 |
Breathing Micelles for Combinatorial Treatment of Rheumatoid Arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Breath Tests; Carbon Monoxi | 2020 |
Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease.
Topics: Aged; Arthritis, Rheumatoid; Carbon Monoxide; Cohort Studies; Dyspnea; Female; Forced Expiratory Vol | 2017 |
The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.
Topics: Aged; Arthritis, Rheumatoid; Carbon Monoxide; Female; Health Status Indicators; Humans; Idiopathic P | 2017 |
Air Pollution as a Potential Determinant of Rheumatoid Arthritis: A Population-based Cohort Study in Taiwan.
Topics: Adult; Air Pollution; Arthritis, Rheumatoid; Carbon Monoxide; Cohort Studies; Comorbidity; Environme | 2017 |
Association between Exposure to Ambient Air Pollution and Rheumatoid Arthritis in Adults.
Topics: Adult; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Arthritis, Rheumatoid; Carbon Monoxid | 2019 |
Synthesis and Evaluation of Carbonic Anhydrase Inhibitors with Carbon Monoxide Releasing Properties for the Management of Rheumatoid Arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Carbon Monoxide; Carbonic Anhydrase Inhibitors | 2019 |
The CO donor CORM-2 inhibits LPS-induced vascular cell adhesion molecule-1 expression and leukocyte adhesion in human rheumatoid synovial fibroblasts.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Binding Sites; Carbon Monoxide; Cell Adhesion; | 2014 |
Preclinical lung disease in early rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Bronchiectasis; Carbon Monoxide; Female; Humans; Lung; Lung Diseases; Prospec | 2016 |
Effect of rituximab on pulmonary function in patients with rheumatoid arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Carbon Monoxide; Female; Follow-Up Studies; Human | 2016 |
Clinical and high resolution computed tomography characteristics of patients with rheumatoid arthritis lung disease.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Asian People; Bronchiectasis; Carbon Monoxide | 2009 |
[BEHAVIOR OF CARBON MONOXIDE DIFFUSION IN CASES OF RHEUMATOID ARTHRITIS, SCLERODERMA SYSTEMIC ERYTHEMATOSUS AND DERMATOMYOSITIS].
Topics: Arthritis; Arthritis, Rheumatoid; Carbon Monoxide; Dermatomyositis; Humans; Lupus Erythematosus, Sys | 1965 |
Carbon monoxide-releasing molecules: a pharmacological expedient to counteract inflammation.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Carbon Monoxide; Cytokines; Heme Oxygenase | 2008 |
Noninvasive diagnosis of pulmonary hemorrhage in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Carbon Monoxide; Child; Echocardiography; Female; Heart Atria; Hemorrhage; Hu | 1983 |
Single-breath pulmonary diffusing capacity. Reference values and application in connective tissue diseases and in various lung diseases.
Topics: Adult; Aged; Arthritis, Rheumatoid; Biopsy, Needle; Carbon Monoxide; Collagen Diseases; Female; Hemo | 1976 |
Pulmonary involvement in patients with rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Carbon Monoxide; Humans; Male; Middle Aged; Pulmonary Diffusing | 1975 |
Regional ventilation and perfusion in silicosis and in the alveolar-capillary block syndrome.
Topics: Adult; Aged; Arthritis, Rheumatoid; Body Surface Area; Bronchitis; Capillaries; Carbon Dioxide; Carb | 1970 |